ImmuLogic Restructures Operations; ALLERVAX(R) Clinical Program on Hold

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
ImmuLogic Restructures Operations; ALLERVAX(R) Clinical Program on Hold
    WALTHAM, Mass., Nov. 24 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) reported today that it is restructuring operations
and that further clinical trials of its ALLERVAX(R) CAT and RAGWEED programs
are on hold.  The Company concluded that the significant additional costs
necessary to commercialize the products were not justified in light of the
Company's other strategic alternatives.  The Company will continue its
technical efforts on two programs: vaccines for drugs of abuse and recombinant
proteins directed to the diagnosis and treatment of allergic diseases.  As
part of the restructuring, the Company intends to reduce headcount and
sublease the majority of its space in its Waltham facility.
    After implementation, the savings from the restructuring will decrease the
net cash spend to approximately $3 million annually.  The cash resources saved
by these actions will permit the Company to pursue other alternatives and it
has retained Hambrecht & Quist to assist in this process.  As of September 30,
1997, the Company had approximately $54 million in cash and investments.
    ImmuLogic is focused on developing treatments for allergies and substance
abuse.  ImmuLogic has a comprehensive worldwide patent portfolio covering the
recombinant production of the most common environmental allergens.  The
Company recently filed an IND for its cocaine vaccine and has an ongoing
nicotine vaccine research program.  The Company's press releases are available
on the Internet at http://www.prnewswire.com or by fax through Company News on Call
at 800-758-5804, ext. 114501.
    This press release contains forward-looking statements that involve a
number of risks and uncertainties.  Among the most important factors that
could cause actual results to differ materially from those indicated by such
forward-looking statements are delays in product development, failure to
obtain required regulatory approvals, and the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996.
SOURCE ImmuLogic Pharmaceuticals